Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a clinical-stage biotechnology company utilizing best-in-class antibody...
Monday, November 11, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Spyre Therapeutics is set to host a conference call and webcast to discuss interim results from their Phase 1 healthy volunteer trial for SPY001, an innovative anti-α4β7 antibody designed to treat inflammatory bowel disease. The event will occur on November 12, 2024. The trial aims to evaluate the safety and effectiveness of this novel therapy. The company's investor relations page will provide access to the live and archived webcast.
Price reaction · baseline $39.575 (2024-11-08 close) · 2 other SYRE headline(s) in the window, move may be shared
day 0 close
-0.6%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+249%
120-day peak, hindsight
Typical move
3.2%
average across 3 past catalysts
Cash runway
~49 mo
Minimal dilution risk
Lead asset
Co-ArgI-PEG modified human arginase I
Phase 2 · Acute Myeloid Leukemia
Full Press Release Details
To access the live and archived webcast, please visit the Investor Relations page of Spyre's website at https://ir.spyre.com/events-and-presentations . The archived webcast will be available for a limited time on the Company's website.